PMV Pharmaceuticals Inc. reported a net loss of $21.1 million for the third quarter ended September 30, 2025, compared to a net loss of $19.2 million in the same period in 2024. Research and development expenses increased to $18.2 million from $16.9 million, primarily due to higher contractual research organization costs related to the advancement of the rezatapopt program. General and administrative expenses decreased to $4.3 million from $4.9 million, mainly due to reduced stock-based compensation and lower facility and operational expenses. As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $129.3 million, expected to provide a cash runway through the first quarter of 2027. Business developments included updated clinical results from the Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt, with a 46% overall response rate observed in the ovarian cancer cohort. PMV Pharmaceuticals plans to submit a New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027.